Total
0
Shares
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Regenerative medicine company Orthocell (OCC) has completed a submission to the U.S. Food and Drug Administration (FDA) for its CelGro device
  • CelGro is a medical device that increases tissue repair and regeneration, while helping to re-join severed or damaged peripheral nerves.
  • The company is seeking 510(k) clearance which, once approved, will confirm that CelGro is a safe and effective product
  • This submission follows positive results from a U.S. FDA guided bone study that showed CelGro is effective in easing bone regeneration when used alongside a bone substitute and a dental implant
  • Orthocell is up 4.11 per cent and shares are trading for 38 cents each

Regenerative medicine company Orthocell (OCC) has completed submission to the U.S. Food and Drug Administration (FDA) for its CelGro device.

The company is seeking 510(k) clearance which, once approved, will confirm that CelGro is a safe and effective product.

This submission follows positive results from a U.S. FDA guided bone study that showed CelGro is effective is easing bone regeneration when used alongside bone substitute and a dental implant.

“This is a significant milestone for Orthocell as we drive our innovative regenerative medicine products into the U.S., the largest global healthcare market,” Managing Director Paul Anderson said.

“We are in a strong position to gain U.S. approval and are actively progressing our U.S. market launch strategy,” he added.

The U.S. submission compliments Orthocell’s current regulatory submissions in Australia for dental bone and soft tissue regeneration applications.

This will be followed by submissions to the States, E.U., and Australia for CelGro to treat crushed or severed nerves and increase tendon repair.

What is CelGro?

CelGro is a unique medical device that increases tissue repair and regeneration, while helping to re-join severed or damaged peripheral nerves.

It has a bilayer structure which features smooth and rough sides to create a bioactive chamber to guide new tissues formations and protect the repair site.

The smooth layer is made up of densely packed collagen (a protein that provides structure to the body) grouped in bundles with abundant pores that allow fluids and nutrients to flow through.

It also prevents external tissue coming to the site of repair.

The rough layer is made up of loosely arranged collagen bundles to provide a scaffold to support new cell growth.

CelGro can be used to treat nerve and tendon repair, as well as dental bone and soft tissue applications.

Orthocell is up 4.11 per cent and shares are trading for 38 cents each at 10:58 am AEST.

OCC by the numbers
More From The Market Herald
Dimerix (ASX:DXB) - Managing Director and CEO, Nina Webster

" Dimerix (ASX:DXB) expands DMX-200 study into Australia

Dimerix (DXB) has entered an agreement with the NHMRC Clinical Trials Centre at the University of Sydney to expand the CLARITY 2.

" ACCC scrambles to halt Virtus Health’s (ASX:VRT) purchase of Healius (ASX:HLS) IVF clinics

The ACCC has taken “a significant step” as it seeks an urgent injunction to stop Virtus Health’s (VRT) proposed acquisition of Adora Fertility
IDT Australia (ASX:IDT) - Chair, Alan Fisher

" IDT Australia (ASX:IDT) signs manufacturing deal with Monash University

IDT Australia (IDT) has entered a master services agreement and services order with Monash University.
Prescient Therapeutics (PTX) - CEO and MD, Steven Yatomi Clarke

" Prescient Therapeutics (ASX:PTX) to present new OmniCAR data at conference

Prescient Therapeutics (PTX) will present new results for its OmniCAR drug at the Cell & Gene Meeting on Mesa in California.